ACADIA Pharmaceuticals Stock Shrugs Off Post-Earnings Bear Notes

ACAD calls are the options of choice today -- a reversal of recent trends

by Emma Duncan

Published on Aug 9, 2018 at 10:45 AM

Shares of drug name ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) touched a five-year low of $12.77 out of the gate, but have since turned higher, as traders shrug off an earnings miss. The firm reported weaker-than-expected second-quarter earnings, and lowered its full-year sales guidance for its Parkinson's drug, Nuplazid. Nevertheless -- and despite mostly negative analyst attention -- ACAD stock is up 8.5% to trade at $15.21.

Analysts have been quick to react to the earnings miss, with no fewer than three price-target cuts recorded so far. Specifically, Cowen lowered its target to $42 from $50, and Stifel cut its target to $14 from $17. Meanwhile, J.P. Morgan Securities slashed its target by nearly 50%, to $26 from $50 -- still a healthy premium to ACAD's current price.

Even with today's bounce, the pharma stock could be due for more bear notes. Currently, four of the six analysts covering Acadia stock sport a "strong buy" rating. Plus, the average 12-month price target of $31.63 is more than double the equity's current perch.

On the charts, ACADIA stock has been in a downtrend since its post-earnings bear gap in late February. The stock gapped lower again in April, after a scathing CNN report detailing the number of deaths associated with Nuplazid. As of yesterday, ACAD's 14-day Relative Strength Index (RSI) sat at 35 -- on the cusp of oversold territory, suggesting today's bounce may have been in the cards.

Options traders were speculating on more downside for ACAD after earnings. Data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows ACADIA Pharmaceuticals stock with a 10-day put/call volume ratio of 2.75, ranking in the 81st percentile of its annual range. This suggests that during the past two weeks, puts have been bought over calls at a faster-than-usual clip.

Today, however, Acadia calls are flying off the shelves at six times the average intraday clip, with more than 2,100 exchanged. That's compared to fewer than 700 ACAD puts.

Halliburton Put Options Pricey Ahead of Earnings
HAL has been struggling since its mid-May highs
Oil Stock's Buy Signal Has Never Been Wrong
The stock has pulled back recently with crude oil prices
CLF Stock Nears Bullish Trendline Ahead of Earnings
Cleveland-Cliffs stock has been a long-term outperformer
From Schaeffer's Pro Traders
Weekly Options Secrets Revealed

Direct from our Schaeffer's traders, your FREE guide to winning with weekly options!


Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Access the #1 Marijuana IPO of 2018
Get ready for an influx of pot stock profits.
China Stock Halted After 300% Spike
The stock has been halted most of the day
Earnings, Fed Minutes Result in See-Saw Week for Stocks
Netflix and a handful of Dow stocks moved on earnings
Access the #1 Marijuana IPO of 2018
Get ready for an influx of pot stock profits.